Ireland - English - HPRA (Health Products Regulatory Authority)

ferring ireland ltd - triptorelin - powder and solvent for suspension for injection - 3.75 milligram(s) - gonadotropin releasing hormone analogues; triptorelin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferring pharmaceuticals ltd - triptorelin acetate - powder and solvent for suspension for injection - 3.75mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

1,000unit) powder and 20ml solvent for solution for infusion vials (takeda uk ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for infusion - 1000unit

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - octreotide - powder and solvent for suspension for injection - 10 milligram(s) - somatostatin and analogues; octreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - octreotide - powder and solvent for suspension for injection - 20 milligram(s) - somatostatin and analogues; octreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - octreotide - powder and solvent for suspension for injection - 30 milligram(s) - somatostatin and analogues; octreotide

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 40 mg/ml - suspension, powder for - excipient ingredients: titanium dioxide; sodium benzoate; citric acid; colloidal anhydrous silica; sodium citrate dihydrate; sucrose; xanthan gum; flavour - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 150 mg (equivalent: cefuroxime, qty 125 mg) - suspension, powder for - excipient ingredients: aspartame; stearic acid; sucrose; povidone; xanthan gum; acesulfame potassium; flavour - zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

500unit) powder and 20ml solvent for solution for infusion vials (takeda uk ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for infusion - 500unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (glaxosmithkline uk ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg